https://hipa.ai/drug/empagliflozin/updates/trial-results-posted-nct05232071-2026-09-09 Hipa.ai en 2026-09-09T00:00:00.000Z Empagliflozin Trial Shows HbA1c Improvement With Lanifibranor https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct05119296-2026-09-09 Hipa.ai en 2026-09-09T00:00:00.000Z Pembrolizumab trial reports no overall responses in thyroid cancer https://hipa.ai/drug/adalimumab/updates/trial-results-posted-nct05322473-2026-09-09 Hipa.ai en 2026-09-09T00:00:00.000Z Adalimumab Trial Shows 36.4% HiSCR75 Response in HS https://hipa.ai/drug/crovalimab/updates/trial-results-posted-nct04958265-2026-09-09 Hipa.ai en 2026-09-09T00:00:00.000Z Crovalimab Trial Results in Pediatric aHUS Show Dialysis Changes https://hipa.ai/drug/dapagliflozin/updates/indication-usage-updated-dapagliflozin-label-effective-2026-2026-09-08 Hipa.ai en 2026-09-08T00:00:00.000Z Dapagliflozin Label Adds Heart Failure Hospitalization Indication https://hipa.ai/drug/canagliflozin/updates/boxed-warning-present-label-metformin-hydrochloride-label-2026-09-08 Hipa.ai en 2026-09-08T00:00:00.000Z Canagliflozin Label Carries Metformin Lactic Acidosis Warning https://hipa.ai/drug/adagrasib/updates/trial-results-posted-nct06039384-2026-09-08 Hipa.ai en 2026-09-08T00:00:00.000Z Adagrasib Combination Trial Results Posted in Solid Tumors https://hipa.ai/drug/orforglipron/updates/trial-results-posted-nct05872620-2026-09-04 Hipa.ai en 2026-09-04T00:00:00.000Z Orforglipron cuts body weight in Phase 3 diabetes trial